Place · Level 3 · Condition
Hypertension
RAAS + 内皮 + 钠钾平衡 · 中国 2.5 亿患者 · DASH RCT · SPRINT 强化降压 (SBP<120) → 2017 ACC/AHA 130/80 切点 · ACEi/ARB 一线
Last updated
Story path
Chapter 1
HTN · what + China
HTN · what + China
The plain version first: the scary thing about high blood pressure isn't any single number — it's that over decades it silently wears down your vessels, heart, kidneys, and eyes, and most people feel nothing the whole time, which is why it's called "the silent killer". Below: the definition, the real numbers in China, and how blood pressure actually climbs.
Hypertension = sustained elevation of blood pressure that, over time → damage to cardiac, cerebral, and renal vasculature → MI / stroke / heart failure / kidney failure.
Diagnostic thresholds (2017 ACC/AHA update):
Normal: < 120 / 80 mmHgElevated: 120-129 / < 80Stage 1 hypertension: 130-139 / 80-89Stage 2 hypertension: ≥ 140 / 90Hypertensive emergency: ≥ 180 / 120 + organ damage
The SPRINT trial (2015 NEJM) tested intensive lowering (SBP < 120) vs standard (< 140) in a high-risk non-diabetic population — the intensive arm cut all-cause mortality by 27%. Note: < 130/80 is the 2017 ACC/AHA guideline cut-point, not SPRINT's target; it was SPRINT's result that pushed 2017 ACC/AHA to move the threshold down from 140/90 to 130/80 — a clinical-guideline paradigm shift noted across the atlas.
Chinese epidemiology (Wang 2018 Circulation, national survey):
Prevalence 27.9% (crude; 23.2% standardized, ~ 245 million patients)Awareness 46.9% / treatment 40.7% / control 15.3%"The silent killer": most patients are asymptomatic until complications appearSalt intake ~ 11 g/day (WHO recommends < 5 g) — China has one of the highest salt intakes worldwide
Why these numbers matter:
Cardiovascular deaths account for 40%+ of all-cause mortality in China (GBD 2019)The number-one modifiable risk factor for cardiovascular disease = hypertensionRaising the control rate from ~15% to 50% (US / Japan level) → about 700,000-1,000,000 fewer deaths per year
Home BP monitoring:
Home measurement is preferred over office measurement (avoids "white-coat" + "masked" hypertension)Twice in the morning (1 h after waking) and twice before bed; take the averageUpper-arm electronic monitors are accurate; wrist and finger monitors are unreliableDiagnosis requires multiple measurements, not a single reading
How blood pressure rises (brief mechanism — next scene goes deeper):
1. Cardiac output ↑ (heart rate × stroke volume) — anxiety + hypervolemia + high sympathetic tone
2. Peripheral resistance ↑ — vasoconstriction + endothelial dysfunction + vascular stiffening
3. Blood volume ↑ — sodium retention + renin–angiotensin–aldosterone system: A hormone chain that controls blood pressure and fluid — when tense it narrows vessels and holds water and sodium. activation
Atlas connections: atherosclerosis (cardiovascular L4) + sleep-apnea (upper-airway collapse + HTN) + endocrine/metabolic-syndrome (second MetSyn criterion) + magnesium/relax (Mg and BP) + potassium-sodium/gradient (Na/K balance basics).
Hypertension = sustained elevation of blood pressure that, over time → damage to cardiac, cerebral, and renal vasculature → MI / stroke / heart failure / kidney failure.
Diagnostic thresholds (2017 ACC/AHA update):
Normal: < 120 / 80 mmHgElevated: 120-129 / < 80Stage 1 hypertension: 130-139 / 80-89Stage 2 hypertension: ≥ 140 / 90Hypertensive emergency: ≥ 180 / 120 + organ damage
The SPRINT trial (2015 NEJM) tested intensive lowering (SBP < 120) vs standard (< 140) in a high-risk non-diabetic population — the intensive arm cut all-cause mortality by 27%. Note: < 130/80 is the 2017 ACC/AHA guideline cut-point, not SPRINT's target; it was SPRINT's result that pushed 2017 ACC/AHA to move the threshold down from 140/90 to 130/80 — a clinical-guideline paradigm shift noted across the atlas.
Chinese epidemiology (Wang 2018 Circulation, national survey):
Prevalence 27.9% (crude; 23.2% standardized, ~ 245 million patients)Awareness 46.9% / treatment 40.7% / control 15.3%"The silent killer": most patients are asymptomatic until complications appearSalt intake ~ 11 g/day (WHO recommends < 5 g) — China has one of the highest salt intakes worldwide
Why these numbers matter:
Cardiovascular deaths account for 40%+ of all-cause mortality in China (GBD 2019)The number-one modifiable risk factor for cardiovascular disease = hypertensionRaising the control rate from ~15% to 50% (US / Japan level) → about 700,000-1,000,000 fewer deaths per year
Home BP monitoring:
Home measurement is preferred over office measurement (avoids "white-coat" + "masked" hypertension)Twice in the morning (1 h after waking) and twice before bed; take the averageUpper-arm electronic monitors are accurate; wrist and finger monitors are unreliableDiagnosis requires multiple measurements, not a single reading
How blood pressure rises (brief mechanism — next scene goes deeper):
1. Cardiac output ↑ (heart rate × stroke volume) — anxiety + hypervolemia + high sympathetic tone
2. Peripheral resistance ↑ — vasoconstriction + endothelial dysfunction + vascular stiffening
3. Blood volume ↑ — sodium retention + renin–angiotensin–aldosterone system: A hormone chain that controls blood pressure and fluid — when tense it narrows vessels and holds water and sodium. activation
Atlas connections: atherosclerosis (cardiovascular L4) + sleep-apnea (upper-airway collapse + HTN) + endocrine/metabolic-syndrome (second MetSyn criterion) + magnesium/relax (Mg and BP) + potassium-sodium/gradient (Na/K balance basics).
临床 · 线划在哪
高血压 (Hypertension) = 持续性血压升高, 长期 → 心脑肾血管损害 → 心梗、中风、心衰、肾衰.诊断切点 (2017 ACC/AHA 更新):
正常: < 120 / 80 mmHg升高: 120-129 / < 801 期高血压: 130-139 / 80-892 期高血压: ≥ 140 / 90高血压急症: ≥ 180 / 120 + 器官损害
SPRINT 试验 (2015 NEJM) 测的是强化降压 (收缩压 < 120) vs 标准 (< 140) 在高危非糖尿病人群里的差异——强化组全因死亡 ↓ 27%. 注意: <130/80 是 2017 ACC/AHA 指南的诊断/治疗切点, 不是 SPRINT 的目标; 正是 SPRINT 的结果推动了 2017 ACC/AHA 把切点从 140/90 下移到 130/80——这是 atlas 上一个临床指南范式转移.
数字 · 中国有多少人在这条船上
中国流行病学 (Wang 2018 Circulation, 全国调查):患病率 27.9% (粗率; 标化 23.2%, ~ 2.45 亿患者)知晓率 46.9% / 治疗率 40.7% / 控制率 15.3%沉默杀手: 大多数患者无症状直到并发症盐摄入 ~ 11 g/天 (WHO 推荐 < 5 g) — 中国是全球盐摄入最高的国家之一
为什么这些数字关键:
中国心血管病死亡占总死亡 40%+ (GBD 2019)心血管病第一可改变风险因子 = 高血压把控制率从 ~15% 提到 50% (像美日水平) → 每年减约 70-100 万死亡
实操 · 血压该怎么量
血压自测:家庭自测优于诊室测 (避免白大衣高血压 + 隐匿性高血压)早上起床后 1h + 睡前各测 2 次, 取平均上臂式电子血压计准确, 腕式 + 手指式不可靠诊断需多次测量, 不要凭一次
与 atlas 其它岛的连接: atherosclerosis (cardiovascular L4) + sleep-apnea (上气道塌陷 + HTN) + endocrine/metabolic-syndrome (MetSyn 第二个标志) + magnesium/relax (Mg 与血压) + potassium-sodium/gradient (Na/K 平衡基础).
Chapter 2
RAAS + endothelium
RAAS + endothelium
Two core axes of blood-pressure regulation:
① renin–angiotensin–aldosterone system: A hormone chain that controls blood pressure and fluid — when tense it narrows vessels and holds water and sodium. system (renin-angiotensin-aldosterone):
The liver makes angiotensinogen; renin released by the kidney cleaves it into angiotensin I; lung ACE then converts that into angiotensin II — a potent vasoconstrictor. Angiotensin II does four things at once: it constricts vessels directly (peripheral resistance ↑); it drives adrenal aldosterone, which retains sodium and excretes potassium to build blood volume; it triggers hypothalamic vasopressin to hold water; and it raises sympathetic activity.
This is why ACEi (enalapril) + ARB (losartan) are first-line HTN drugs — they block this axis at multiple points.
② Vascular endothelium + nitric oxide: A small signal molecule from the vessel lining that relaxes the vessel-wall muscle so the vessel widens. pathway:
Endothelial cells produce nitric oxide (NO) → vascular smooth muscle cGMP ↑ → vasodilationHealthy: normal NO production → compliant vesselsEndothelial dysfunction: ROS ↑ (smoking / hyperglycemia / dyslipidemia / aging) → NO oxidised → vessels fail to dilateDietary nitrate (leafy greens + beetroot) → oral bacteria → nitrite → systemic NO pool (see atlas citrulline L4)This is the mechanistic basis for DASH and beetroot lowering BP
③ Sodium-potassium balance (covered in detail in atlas potassium-sodium/gradient L4):
High sodium + low potassium = HTN driverDaily sodium < 2300 mg + potassium ≥ 3500 mg → BP -5-10 mmHg (Aburto 2013 BMJ meta-analysis)Typical Chinese intake: sodium 4500 mg+ / potassium 1500 mg — completely inverted
Secondary vs primary hypertension:
Primary (~ 90-95%): multifactorial / genetic + lifestyleSecondary (~ 5-10%):Renovascular stenosis (abnormal RAAS activation)GlomerulonephritisPheochromocytoma (catecholamine-secreting adrenal tumor)Cushing's syndrome (cortisol)Primary aldosteronism (Conn's syndrome) — unilateral adrenal adenoma, severely under-diagnosed, accounting for ~ 10-20% of resistant hypertensionObstructive sleep apnea (OSA) — covered in atlas sleep-apnea L4Oral contraceptives / steroids / chronic NSAIDs / decongestantsResistant hypertension (still > 140/90 on 3 drugs) mandates secondary work-up
Practice:
HTN + young (< 40) + severe → must screen for secondary causesHTN + hypokalemia → screen for primary aldosteronism (often missed)HTN + snoring / daytime sleepiness → screen for OSA
① renin–angiotensin–aldosterone system: A hormone chain that controls blood pressure and fluid — when tense it narrows vessels and holds water and sodium. system (renin-angiotensin-aldosterone):
The liver makes angiotensinogen; renin released by the kidney cleaves it into angiotensin I; lung ACE then converts that into angiotensin II — a potent vasoconstrictor. Angiotensin II does four things at once: it constricts vessels directly (peripheral resistance ↑); it drives adrenal aldosterone, which retains sodium and excretes potassium to build blood volume; it triggers hypothalamic vasopressin to hold water; and it raises sympathetic activity.
This is why ACEi (enalapril) + ARB (losartan) are first-line HTN drugs — they block this axis at multiple points.
② Vascular endothelium + nitric oxide: A small signal molecule from the vessel lining that relaxes the vessel-wall muscle so the vessel widens. pathway:
Endothelial cells produce nitric oxide (NO) → vascular smooth muscle cGMP ↑ → vasodilationHealthy: normal NO production → compliant vesselsEndothelial dysfunction: ROS ↑ (smoking / hyperglycemia / dyslipidemia / aging) → NO oxidised → vessels fail to dilateDietary nitrate (leafy greens + beetroot) → oral bacteria → nitrite → systemic NO pool (see atlas citrulline L4)This is the mechanistic basis for DASH and beetroot lowering BP
③ Sodium-potassium balance (covered in detail in atlas potassium-sodium/gradient L4):
High sodium + low potassium = HTN driverDaily sodium < 2300 mg + potassium ≥ 3500 mg → BP -5-10 mmHg (Aburto 2013 BMJ meta-analysis)Typical Chinese intake: sodium 4500 mg+ / potassium 1500 mg — completely inverted
Secondary vs primary hypertension:
Primary (~ 90-95%): multifactorial / genetic + lifestyleSecondary (~ 5-10%):Renovascular stenosis (abnormal RAAS activation)GlomerulonephritisPheochromocytoma (catecholamine-secreting adrenal tumor)Cushing's syndrome (cortisol)Primary aldosteronism (Conn's syndrome) — unilateral adrenal adenoma, severely under-diagnosed, accounting for ~ 10-20% of resistant hypertensionObstructive sleep apnea (OSA) — covered in atlas sleep-apnea L4Oral contraceptives / steroids / chronic NSAIDs / decongestantsResistant hypertension (still > 140/90 on 3 drugs) mandates secondary work-up
Practice:
HTN + young (< 40) + severe → must screen for secondary causesHTN + hypokalemia → screen for primary aldosteronism (often missed)HTN + snoring / daytime sleepiness → screen for OSA
机制 · 钠和钾的那场拉锯
钠把水一起拉进血管, 钾站在相反的一边。中国人的餐桌恰好把这对比例拧反了: 盐罐给得太多, 蔬菜豆类给得太少。③ 钠钾平衡 (atlas potassium-sodium/gradient L4 详讲):
高钠 + 低钾 = 高血压驱动每日钠 < 2300 mg + 钾 ≥ 3500 mg → 血压 -5-10 mmHg (Aburto 2013 BMJ meta)中国典型摄入: 钠 4500 mg+ / 钾 1500 mg — 完全反向
临床 · 不是每个高血压都是原发的
继发性 vs 原发性高血压:原发性 (~ 90-95%): 多因素、遗传 + 生活方式综合继发性 (~ 5-10%):肾血管狭窄 (renin–angiotensin–aldosterone system: A hormone chain that controls blood pressure and fluid — when tense it narrows vessels and holds water and sodium. 异常活化)肾小球肾炎嗜铬细胞瘤 (肾上腺肿瘤分泌儿茶酚胺)库欣综合征 (皮质醇)原发性醛固酮增多症 (Conn 综合征) —— 单侧肾上腺腺瘤, 被严重低诊, 约占难治性高血压 10-20%睡眠呼吸暂停 (OSA) — atlas sleep-apnea L4 讲过避孕药、类固醇 / NSAID 长期、减充血剂难治性高血压 (3 种药仍 > 140/90) 必须查继发性
实操:
高血压 + 年轻 (< 40) + 严重 → 必查继发性高血压 + 低钾血症 → 查原发性醛固酮增多症 (常被误诊)高血压 + 鼾声、白天嗜睡 → 查 OSA
Conn syndrome · the missed diagnosis
Primary aldosteronism (PA, formerly Conn's syndrome) is the most severely under-diagnosed treatable cause of hypertension.Real epidemiology:
Historical underestimate: PA was thought to account for only 1-2% of HTNModern studies (Funder 2016 Endocr Soc + Brown 2020 Ann Intern Med): 5-10% of general HTN, ≥ 20% of resistant HTN, ≥ 50% of HTN + hypokalemiaIn other words, of China's 250 million HTN patients, an estimated 10-20 million have PA, yet < 1% are diagnosed
Mechanism:
Unregulated aldosterone secretion from the adrenal zona glomerulosa (unilateral adenoma / bilateral hyperplasia / rare carcinoma)renin–angiotensin–aldosterone system: A hormone chain that controls blood pressure and fluid — when tense it narrows vessels and holds water and sodium.-independent — uncoupled from normal aldosterone regulationAldosterone ↑ → sodium retention + potassium excretion + blood volume ↑ + vascular injury (BP-independent fibrotic effect)
Clinical clues (any one warrants screening):
1. Resistant hypertension: ≥ 140/90 despite 3 drugs (one a diuretic)
2. HTN + spontaneous or drug-induced hypokalemia (K < 3.5)
3. HTN + adrenal incidentaloma
4. Early-onset HTN (< 40 y/o) or severe HTN (> 160/100)
5. HTN + first-degree relative with PA
6. HTN + OSA
7. Any HTN where low-sodium / diuretic treatment is appropriate but works poorly
Screening (first-line):
Plasma aldosterone / renin activity ratio (ARR)Threshold: ARR > 30 ng/dL ÷ ng/mL/h (lab-dependent)Prerequisite: patient off or switched antihypertensives for 4-6 weeks (ACEi/ARB/diuretics/β-blockers distort ARR); maintain on CCB / α-blockerIf unable to stop drugs: maintaining ACEi/ARB suppresses ARR → a negative result cannot be trusted; a high ARR still suggests PA
Confirmation (via endocrinology):
One of four confirmatory tests: oral salt load / fludrocortisone suppression / captopril / IV salineImaging: 4-phase contrast adrenal CTLateralisation: adrenal venous sampling (AVS) — distinguishes unilateral adenoma vs bilateral hyperplasia (entirely different treatments)
Treatment (by type):
Unilateral adenoma: laparoscopic adrenalectomy → 30-60% of patients are fully cured of HTN (no drugs needed), the rest substantially improvedBilateral hyperplasia: lifelong spironolactone / eplerenone + sodium restriction
Why this story matters:
A curable cause of hypertension — early diagnosis = substantially lower long-term cardiovascular riskA 30-year-overlooked clinical reality — Brown 2020 rang the bell again with NHANES + multi-center dataAlcohol / OSA / psychological stress are widely discussed, while PA remains "a specialist's topic" with little patient-facing education
Practice:
Any resistant HTN / HTN + hypokalemia: request an ARR5-10% of general HTN still has PA, but routine screening is not recommended (limited negative predictive value + many false positives)See endocrinology / hypertension specialist, not just a generalist
Atlas closure: endocrine/metabolic-syndrome + cardiovascular/atherosclerosis + sleep-apnea (OSA + PA comorbidity is high).
Chapter 3
DASH diet · A-tier
DASH diet · A-tier
DASH (Dietary Approaches to Stop Hypertension) is one of the most classic dietary RCTs on the atlas:
DASH RCT (Appel 1997 NEJM, NHLBI-funded):
N = 459 hypertensive + prehypertensive patients3 arms over 8 weeks:Control: typical American dietFruits-and-vegetables arm: more produceDASH arm: more fruit / vegetables / whole grains / low-fat dairy / lean meat / nuts + less processed meat / soft drinks / red meat
Results (8 weeks):
DASH arm SBP ↓ 11.4 / vitamin D-binding protein: The blood transport protein that carries vitamin D to organs. ↓ 5.5 (in hypertensive patients)Stronger than many BP monotherapiesThe produce-only arm was intermediate; the control was unchanged
DASH-Sodium follow-up (Sacks 2001 NEJM):
DASH × three sodium levels (high / medium / low)Low-sodium DASH vs high-sodium typical diet: SBP ↓ 12 mmHg
DASH composition (at 2000 kcal/day):
Vegetables 4-5 servings (1 serving = 1 cup raw / 0.5 cup cooked)Fruit 4-5 servingsWhole grains 6-8 servingsLow-fat dairy / yoghurt 2-3 servingsLean meat / fish / egg ≤ 6 servings/dayNuts / legumes / seeds 4-5 servings/weekLimit: added sugar / processed meat / soft drinks / sodium < 2300 mg
DASH vs Mediterranean:
Mediterranean emphasises olive oil + fish + red wine + whole grainsDASH emphasises low-fat dairy + K/Mg loadingSimilar BP-lowering effect, both long-term sustainableChinese implementation: "whole grains + lots of vegetables + less salt + more fish, less red meat" = culturally-adapted DASH
The truth about "less salt":
Chinese dietary sodium sources are mostly cooking salt + soy sauce + condiments (~ 70%), unlike Western diets where ~ 70% comes from packaged foodIn practice: halve soy sauce + separate dipping sauces + add salt at the end + choose sodium-free or low-sodium saltLow-sodium salt (LightSALT): NaCl + KCl mix (China Salt Substitute Trial 2021 NEJM: mortality ↓ 12% + stroke ↓ 14%) — Chinese-domestic 21K RCT with global guideline-level significance
Practical "more potassium":
Dark leafy greens / banana / avocado / sweet potato / legumes / dried fruitCaution in CKD patients — impaired potassium metabolism
Exercise:
150 min/week moderate aerobic → SBP ↓ 5-7 mmHgStrength training → synergisticHIIT may be even more effective but requires safety assessment
Quitting smoking:
Smoking → short-term SBP ↑ 5-10, long-term endothelial damageBenefit of quitting: substantially lower CV risk at 1 year, near non-smoker risk at 5 years
Moderate alcohol:
Alcohol > 20-30 g/day → SBP ↑Stopping alcohol → SBP ↓ 3-5 mmHg within weeksSee atlas alcohol-metabolism (the J-curve has been overturned)
DASH RCT (Appel 1997 NEJM, NHLBI-funded):
N = 459 hypertensive + prehypertensive patients3 arms over 8 weeks:Control: typical American dietFruits-and-vegetables arm: more produceDASH arm: more fruit / vegetables / whole grains / low-fat dairy / lean meat / nuts + less processed meat / soft drinks / red meat
Results (8 weeks):
DASH arm SBP ↓ 11.4 / vitamin D-binding protein: The blood transport protein that carries vitamin D to organs. ↓ 5.5 (in hypertensive patients)Stronger than many BP monotherapiesThe produce-only arm was intermediate; the control was unchanged
DASH-Sodium follow-up (Sacks 2001 NEJM):
DASH × three sodium levels (high / medium / low)Low-sodium DASH vs high-sodium typical diet: SBP ↓ 12 mmHg
DASH composition (at 2000 kcal/day):
Vegetables 4-5 servings (1 serving = 1 cup raw / 0.5 cup cooked)Fruit 4-5 servingsWhole grains 6-8 servingsLow-fat dairy / yoghurt 2-3 servingsLean meat / fish / egg ≤ 6 servings/dayNuts / legumes / seeds 4-5 servings/weekLimit: added sugar / processed meat / soft drinks / sodium < 2300 mg
DASH vs Mediterranean:
Mediterranean emphasises olive oil + fish + red wine + whole grainsDASH emphasises low-fat dairy + K/Mg loadingSimilar BP-lowering effect, both long-term sustainableChinese implementation: "whole grains + lots of vegetables + less salt + more fish, less red meat" = culturally-adapted DASH
The truth about "less salt":
Chinese dietary sodium sources are mostly cooking salt + soy sauce + condiments (~ 70%), unlike Western diets where ~ 70% comes from packaged foodIn practice: halve soy sauce + separate dipping sauces + add salt at the end + choose sodium-free or low-sodium saltLow-sodium salt (LightSALT): NaCl + KCl mix (China Salt Substitute Trial 2021 NEJM: mortality ↓ 12% + stroke ↓ 14%) — Chinese-domestic 21K RCT with global guideline-level significance
Practical "more potassium":
Dark leafy greens / banana / avocado / sweet potato / legumes / dried fruitCaution in CKD patients — impaired potassium metabolism
Exercise:
150 min/week moderate aerobic → SBP ↓ 5-7 mmHgStrength training → synergisticHIIT may be even more effective but requires safety assessment
Quitting smoking:
Smoking → short-term SBP ↑ 5-10, long-term endothelial damageBenefit of quitting: substantially lower CV risk at 1 year, near non-smoker risk at 5 years
Moderate alcohol:
Alcohol > 20-30 g/day → SBP ↑Stopping alcohol → SBP ↓ 3-5 mmHg within weeksSee atlas alcohol-metabolism (the J-curve has been overturned)
研究 · 这场试验是怎么做的
DASH (Dietary Approaches to Stop Hypertension) 是 atlas 上最经典的饮食 RCT 之一:DASH RCT (Appel 1997 NEJM, NHLBI 出资):
N = 459 高血压 + 高血压前期患者3 组 8 周饮食:对照: 典型美国饮食水果蔬菜组: 多水果蔬菜DASH 组: 多水果、蔬菜、全谷、低脂奶、瘦肉、坚果 + 少加工肉、软饮、红肉
结果 (8 周):
DASH 组 SBP ↓ 11.4 / vitamin D-binding protein: The blood transport protein that carries vitamin D to organs. ↓ 5.5 (高血压患者)比许多降压药单药效果还强水果蔬菜组中间, 对照无变化
DASH-Sodium 后续 (Sacks 2001 NEJM):
DASH × 三种钠水平 (高、中 / 低)低钠 DASH 比高钠典型饮食 SBP ↓ 12 mmHg
实操 · 一天该吃成什么样
DASH 饮食构成 (按 2000 kcal/天):蔬菜 4-5 份 (1 份 = 1 杯生 / 0.5 杯熟)水果 4-5 份全谷 6-8 份低脂奶、酸奶 2-3 份瘦肉、鱼 / 蛋 ≤ 6 份/天坚果、豆 / 籽 4-5 份/周限制: 加工糖、加工肉、软饮、钠 < 2300 mg
DASH vs Mediterranean:
Mediterranean 更强调橄榄油 + 鱼 + 红酒 + 全谷DASH 更强调低脂奶 + 钾镁补充降压效果相似, 长期可持续中国实操: 全谷 + 大量蔬菜 + 少盐 + 多鱼少红肉 = 文化适配 DASH
实操 · 盐罐和酱油瓶
少盐 的真实:中国饮食盐源主要是烹饪用盐 + 酱油 + 调味品 (~ 70%), 不像欧美包装食品 (~ 70%)实操: 酱油减半 + 蘸料分开 + 出锅前再加盐 + 选择无钠或低钠盐低钠盐 (LightSALT): NaCl + KCl 混合 (China Salt Substitute Trial 2021 NEJM: 死亡 ↓ 12% + 中风 ↓ 14%) — 中国本土 21K RCT, 全球性意义
多钾 的实操:
深绿叶菜、香蕉、鳄梨、红薯、豆类、干果CKD 患者慎用 — 钾代谢障碍
Salt substitute deep dive
The China Salt Substitute Study (SSaSS, Neal 2021 NEJM) is the most important domestic Chinese cardiovascular RCT on the atlas, with global guideline-level significance.Why this trial is especially important for China:
Chinese per-capita salt intake ~ 11 g/day — one of the highest worldwide (WHO recommends < 5 g)70% comes from cooking salt + soy sauce + condiments (vs ~ 70% from packaged food in the West) → intervention is possible at the individual / household levelCardiovascular deaths account for 40%+ of all-cause mortality in China; HTN is the leading modifiable risk factorOverall salt reduction is hard (taste habits) → salt substitution becomes a smart intermediate path
Trial design:
N = 20,995 (across 600 rural communities in 5 northern Chinese provinces)Eligibility: prior stroke, OR aged 60+ with elevated blood pressure (either one; 88% of those enrolled had HTN)Intervention arm: low-sodium salt (LightSALT) = 75% NaCl + 25% KCl, replacing household cooking saltControl arm: regular salt (100% NaCl)Follow-up ~ 5 years
Results (primary endpoints):
Stroke ↓ 14% (HR 0.86, 95% CI 0.77-0.96, p = 0.006)MACE (MI + stroke + CV death) ↓ 13%All-cause death ↓ 12%Safety: no increase in clinically-significant hyperkalemia (the major concern was dispelled)
Why this is a "trial of the century":
N = 21,000 Chinese locals — ordinary populations, not elite hospitalsSimple intervention: change the salt, no drugs / devices requiredHuge public-health implication: scaled nationally → about 450,000 fewer cardiovascular deaths per year (Marklund 2020 modelling)Together with SPRINT (2015 NEJM intensive BP control), it is one of the two landmark trials in BP-lowering
Practice:
Where to buy "low-sodium / potassium salt": common in Chinese supermarkets, labelled "light salt" or "low-sodium salt"; major brands include Zhong Yan (China Salt)Price: slightly more than regular salt (¥3-5 per pack vs ¥2-3), but much cheaper than antihypertensive drugsSame 1 g of salt, but 25% less sodium + 25% more potassium — a bidirectional interventionUsed like regular salt, with similar taste (a slight metallic bitterness that most people don't notice)
Contraindicated populations (important):
Chronic kidney disease (CKD stage 3-5, eGFR < 30) — impaired potassium excretion, hyperkalemia riskOn ACEi / ARB / spironolactone / eplerenone without renal monitoring — hyperkalemia riskCKD + ACEi/ARB combination: strict contraindicationNormal renal function + not on K-sparing drugs: safe
Real salt reduction (the ultimate goal):
Target: WHO < 5 g/day (about one teaspoon)Practice:Halve soy sauce + try concentrated low-sodium soySeparate dipping sauces (dip before eating, do not mix in)Salt at the end of cooking + do not pre-salt meatReduce / cut pickled vegetablesRead food labels for sodium: < 1.5 g Na/100 g qualifies as low-sodiumProcess: taste buds adapt within 3-4 weeks; afterwards, regular-salt food tastes too salty
Potassium-rich foods (synergistic with substitute salt):
1 banana (~ 400 mg)1 large mango (~ 320 mg)1/2 avocado (~ 480 mg)1 medium cooked sweet potato (~ 540 mg)1 cup cooked spinach (~ 840 mg)1 cup cooked legumes (~ 700 mg)Target: 3500 mg/day (Chinese NHANES average is only 1500 mg)
Atlas position:
The China Salt Substitute Trial is China's biggest single contribution to global nutrition medicine featured on the atlasSalt substitution = the highest-ROI ¥5/month intervention for Chinese householdsIt is not "perfect" — it is a "realistic path to substantial improvement"
实操 · 除了吃, 还有三个开关
运动:中等强度有氧 150 分钟/周 → SBP ↓ 5-7 mmHg力量训练 → 协同效应HIIT (高强度间歇) 可能效果更好但安全性需评估
戒烟:
吸烟 → 短期 SBP ↑ 5-10, 长期内皮损伤戒烟收益: 1 年后心血管风险显著降, 5 年后接近不吸烟者
适量酒精:
酒精剂量 > 20-30 g/天 → SBP ↑戒酒 → 数周内 SBP ↓ 3-5 mmHg见 atlas alcohol-metabolism (J 曲线已被推翻)
Chapter 4
BP meds · 5 classes
BP meds · 5 classes
5 classes of first-line antihypertensives (international consensus):
① ACEi / ARB (renin–angiotensin–aldosterone system: A hormone chain that controls blood pressure and fluid — when tense it narrows vessels and holds water and sodium. inhibition):
ACEi: captopril / enalapril / perindopril / ramiprilARB: valsartan / irbesartan / losartan / telmisartanMechanism: blocks angiotensin II formation (ACEi) or receptor (ARB)Indications: HTN + HF + CKD + diabetic nephropathy protectionSide effects: ACEi → dry cough (10-20%) (bradykinin accumulation) — switch to ARB; hyperkalemia + acute kidney injury (contraindicated in bilateral renal-artery stenosis)Pregnancy contraindicated (teratogenic)
② Calcium channel blockers (CCB):
Dihydropyridines: amlodipine / nifedipine / lacidipine — primarily vasodilatorsNon-dihydropyridines: verapamil / diltiazem — also reduce heart rateIndications: HTN + the elderly + anginaSide effects: ankle edema (amlodipine 5-15%) + tachycardia + gingival hyperplasiaStrengths: especially effective in older patients + Black populations (relatively weak RAAS suppression in these groups)
③ Diuretics:
Thiazides: hydrochlorothiazide / indapamide — reduce blood volume + moderate BP-loweringLoop diuretics: furosemide — HF / emergencyK-sparing diuretics: spironolactone / eplerenone — aldosterone antagonists (resistant HTN + HF)Side effects: hypokalemia + hyponatremia + gout (thiazides) + hyperglycemiaStrengths: cheap + long safety record + synergistic when combined
④ β-blockers:
Bisoprolol / metoprolol / atenololMechanism: ↓ heart rate + ↓ cardiac output + ↓ reninIndications: HTN + angina + arrhythmia + post-MISide effects: fatigue + cold extremities + asthma worsening + sexual dysfunctionNo longer first choice for uncomplicated HTN (unless a comorbid indication exists)
⑤ Others:
α-blockers (prazosin) — dual indication for BPH + HTNDirect vasodilators (minoxidil, many side effects — not first-line)Central agents (clonidine, Parkinsonian side effects — not first-line)
Combination strategy (2018 ESC/ESH):
Most patients start with two-drug combinations (single-pill combinations improve adherence)Classic combinations: ACEi/ARB + CCB / diuretic (synergy + complementary side-effect profile)"ABCD" initiation: A (ACEi/ARB) + B (β-blocker, selective) + C (CCB) + D (diuretic)
New drugs (2024-2025):
Zilebesiran: liver-targeted RNAi silencing angiotensinogen → one injection lowers BP for months (positive Phase II, awaiting Phase III)Aprocitentan: dual endothelin antagonist — resistant HTN, FDA-approved March 2024glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. (semaglutide): lowers BP partly indirectly via weight loss
Adherence is the biggest clinical challenge:
50% of patients stop or skip doses within 1 yearSingle-pill combinations + long-acting + morning dosing + app reminders → ↑ adherence"Drugs for life" is not absolute — some early-stage + large-weight-loss + smoking-cessation + alcohol-limiting patients can taper
① ACEi / ARB (renin–angiotensin–aldosterone system: A hormone chain that controls blood pressure and fluid — when tense it narrows vessels and holds water and sodium. inhibition):
ACEi: captopril / enalapril / perindopril / ramiprilARB: valsartan / irbesartan / losartan / telmisartanMechanism: blocks angiotensin II formation (ACEi) or receptor (ARB)Indications: HTN + HF + CKD + diabetic nephropathy protectionSide effects: ACEi → dry cough (10-20%) (bradykinin accumulation) — switch to ARB; hyperkalemia + acute kidney injury (contraindicated in bilateral renal-artery stenosis)Pregnancy contraindicated (teratogenic)
② Calcium channel blockers (CCB):
Dihydropyridines: amlodipine / nifedipine / lacidipine — primarily vasodilatorsNon-dihydropyridines: verapamil / diltiazem — also reduce heart rateIndications: HTN + the elderly + anginaSide effects: ankle edema (amlodipine 5-15%) + tachycardia + gingival hyperplasiaStrengths: especially effective in older patients + Black populations (relatively weak RAAS suppression in these groups)
③ Diuretics:
Thiazides: hydrochlorothiazide / indapamide — reduce blood volume + moderate BP-loweringLoop diuretics: furosemide — HF / emergencyK-sparing diuretics: spironolactone / eplerenone — aldosterone antagonists (resistant HTN + HF)Side effects: hypokalemia + hyponatremia + gout (thiazides) + hyperglycemiaStrengths: cheap + long safety record + synergistic when combined
④ β-blockers:
Bisoprolol / metoprolol / atenololMechanism: ↓ heart rate + ↓ cardiac output + ↓ reninIndications: HTN + angina + arrhythmia + post-MISide effects: fatigue + cold extremities + asthma worsening + sexual dysfunctionNo longer first choice for uncomplicated HTN (unless a comorbid indication exists)
⑤ Others:
α-blockers (prazosin) — dual indication for BPH + HTNDirect vasodilators (minoxidil, many side effects — not first-line)Central agents (clonidine, Parkinsonian side effects — not first-line)
Combination strategy (2018 ESC/ESH):
Most patients start with two-drug combinations (single-pill combinations improve adherence)Classic combinations: ACEi/ARB + CCB / diuretic (synergy + complementary side-effect profile)"ABCD" initiation: A (ACEi/ARB) + B (β-blocker, selective) + C (CCB) + D (diuretic)
New drugs (2024-2025):
Zilebesiran: liver-targeted RNAi silencing angiotensinogen → one injection lowers BP for months (positive Phase II, awaiting Phase III)Aprocitentan: dual endothelin antagonist — resistant HTN, FDA-approved March 2024glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. (semaglutide): lowers BP partly indirectly via weight loss
Adherence is the biggest clinical challenge:
50% of patients stop or skip doses within 1 yearSingle-pill combinations + long-acting + morning dosing + app reminders → ↑ adherence"Drugs for life" is not absolute — some early-stage + large-weight-loss + smoking-cessation + alcohol-limiting patients can taper
临床 · 每一类各自的坑
ACEi / ARB: 多数人的一线, 合并心衰、糖尿病肾病时还能护肾。常见的坑是 ACEi 会让一小部分人 (约 10-20%) 干咳, 换成 ARB 就好; 两者都可能升血钾, 而且孕期禁用。CCB (氨氯地平这类): 对老年人尤其好使, 代价是有些人脚踝会水肿。
利尿剂 (氢氯噻嗪这类): 便宜、数据老到、和前两类联用很搭; 其中螺内酯这类保钾利尿剂, 是难治性高血压的加药选择。
β 受体阻滞剂 (比索洛尔这类): 现在不再是单纯高血压的首选, 除非同时有心绞痛、心律不齐、心梗史这些额外理由。
实操 · 联用、坚持, 和路上的新药
联用: 多数人一开始就该两种低剂量联用, 常做成一片复方, 好记也好坚持——不同机制互补, 副作用还互相抵消。坚持: 差不多一半人一年内就会漏服或自行停药, 而降压药的收益全靠长期。至于是不是一辈子都得吃, 并非绝对: 早期患者若大幅减重、戒烟、限酒, 有机会在医生指导下减量, 但绝不能自己突然停。
新药也在路上: 一针能压几个月的肝靶向 RNAi (zilebesiran)、给难治性高血压用的内皮素拮抗剂 (aprocitentan, 2024 年获批), 以及顺带降压的 glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. 减重药。
Chapter 5
Decision tree
Decision tree
"My BP is 130-140 / 150 — what do I do?":
Q1: What is your BP range?
120-129 / < 80 (elevated): lifestyle is sufficient130-139 / 80-89 (Stage 1 HTN): 3-6 months of lifestyle; if not at goal, add medication140-159 / 90-99 (Stage 2 HTN): start lifestyle and medication together≥ 160 / 100: immediate medication + lifestyle≥ 180 / 120: emergency, seek care
Q2: What additional risks do you have?
CVD history / diabetes / CKD / ≥ 65 y/o: tighter target (< 130/80)Smoking / high LDL / high BMI / family history: weighted aggressivenessPregnancy: managed separately (preeclampsia risk, ACEi/ARB contraindicated)
Q3: 5 lifestyle levers (ordered by ROI):
① Weight loss (BMI > 25): every 1 kg loss → SBP ↓ 1 mmHg
② Salt reduction (China: mainly cooking salt): 6 g → 3 g → SBP ↓ 5-8 mmHg
③ More potassium (greens + banana + sweet potato + legumes): SBP ↓ 4-5 mmHg
④ Exercise (150 min/week moderate aerobic): SBP ↓ 5-7 mmHg
⑤ Alcohol limitation (< 1 drink/day): SBP ↓ 3-5 mmHg
Q1: What is your BP range?
120-129 / < 80 (elevated): lifestyle is sufficient130-139 / 80-89 (Stage 1 HTN): 3-6 months of lifestyle; if not at goal, add medication140-159 / 90-99 (Stage 2 HTN): start lifestyle and medication together≥ 160 / 100: immediate medication + lifestyle≥ 180 / 120: emergency, seek care
Q2: What additional risks do you have?
CVD history / diabetes / CKD / ≥ 65 y/o: tighter target (< 130/80)Smoking / high LDL / high BMI / family history: weighted aggressivenessPregnancy: managed separately (preeclampsia risk, ACEi/ARB contraindicated)
Q3: 5 lifestyle levers (ordered by ROI):
① Weight loss (BMI > 25): every 1 kg loss → SBP ↓ 1 mmHg
② Salt reduction (China: mainly cooking salt): 6 g → 3 g → SBP ↓ 5-8 mmHg
③ More potassium (greens + banana + sweet potato + legumes): SBP ↓ 4-5 mmHg
④ Exercise (150 min/week moderate aerobic): SBP ↓ 5-7 mmHg
⑤ Alcohol limitation (< 1 drink/day): SBP ↓ 3-5 mmHg
实操 · 风险加权 + 五个杠杆排序
Q2: 你的额外风险?心血管病史、糖尿病 / CKD / ≥ 65 岁: 目标更严 (< 130/80)吸烟、高 LDL / 高 BMI / 家族史: 加权治疗怀孕: 单独管理 (preeclampsia 风险, ACEi/ARB 禁忌)
Q3: 生活方式 5 大杠杆 (按性价比排序):
①减重 (BMI > 25): 每减 1 kg → SBP ↓ 1 mmHg
②减盐 (中国主要烹饪用盐): 6 g → 3 g → SBP ↓ 5-8 mmHg
③多钾 (绿叶 + 香蕉 + 红薯 + 豆): SBP ↓ 4-5 mmHg
④运动 (150 min/周 中等有氧): SBP ↓ 5-7 mmHg
⑤限酒 (< 1 杯/天): SBP ↓ 3-5 mmHg
Monitoring + complications + warnings + atlas
Q4: Monitoring:Home BP monitor (upper-arm, calibrated yearly)Two readings in the morning and two before bed, take the averageNot at goal = 3-month average still ≥ 130/80 (not a single reading)"White-coat HTN": high in office + normal at home — no drugs needed"Masked HTN": normal in office + high at home — must be treated (high-risk phenotype, CV events similar to sustained HTN)
Q5: Monitoring for complications:
Heart: ECG + echocardiogram (LVH)Kidney: urine albumin / creatinine + eGFREye: fundoscopy (hypertensive retinopathy)Brain: only if symptomatic
Q6: Commonly overlooked:
Obstructive sleep apnea (OSA) (atlas sleep-apnea L4): snoring + daytime sleepiness + HTN → polysomnographyPrimary aldosteronism (Conn's): resistant HTN + hypokalemia + unilateral adrenal adenoma — check renin / aldosteroneHyperthyroidism / hypothyroidism / Hashimoto's (atlas hashimoto L4)Depression / anxiety + chronic stress: hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol. + sympathetic activation → HTN
Important warnings:
"BP drugs are for life" is not absolute — some early-stage + weight-loss + smoking-cessation patients can taper (with physician supervision, do not stop on your own)Self-discontinuation = acute rebound + cardiovascular events — forbiddenChronic NSAIDs / decongestants / some TCM (liquorice) / certain supplements can raise BP — take note
Self-check checklist:
Annually: home BP self-measurement + physical examPriority 35+ y/oAny "elevated" or Stage 1 → 6 months of lifestyle intervention + re-measurementNot at goal → internal-medicine consultation
Atlas connections:
alcohol-metabolism + UPF + fructose-metabolism (dietary drivers)sleep-apnea + shift-work + insomnia (sleep drivers)endocrine/metabolic-syndrome (MetSyn)cardiovascular/atherosclerosis L4 (complication mechanisms)citrulline + magnesium + K-Na (nutritional tools)
Atlas position: hypertension is China's leading modifiable cardiovascular risk — early detection + early intervention + long-term management is one of the highest-ROI interventions for both the healthcare system and the individual. It is not a "disease of the elderly"; it is a metabolic-vascular state that begins at 35.
References · 6
- SPRINT Research Group. (2015). A randomized trial of intensive versus standard blood-pressure control. New England Journal of Medicine, 373(22), 2103-2116. 10.1056/NEJMoa1511939
- Wang, Z., Chen, Z., Zhang, L., Wang, X., Hao, G., Zhang, Z., et al. (2018). Status of hypertension in China: results from the China Hypertension Survey, 2012-2015. Circulation, 137(22), 2344-2356. 10.1161/CIRCULATIONAHA.117.032380
- Aburto, N. J., Hanson, S., Gutierrez, H., Hooper, L., Elliott, P., & Cappuccio, F. P. (2013). Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ, 346, f1378. Higher potassium intake lowered systolic BP by ~3.5 mmHg in people with hypertension and was associated with lower stroke risk (RR 0.76). 10.1136/bmj.f1378
- Appel, L. J., Moore, T. J., Obarzanek, E., Vollmer, W. M., Svetkey, L. P., Sacks, F. M., et al. (1997). A clinical trial of the effects of dietary patterns on blood pressure (DASH). New England Journal of Medicine, 336(16), 1117-1124. 10.1056/NEJM199704173361601
- Neal, B., Wu, Y., Feng, X., Zhang, R., Zhang, Y., Shi, J., et al. (2021). Effect of salt substitution on cardiovascular events and death (SSaSS). New England Journal of Medicine, 385(12), 1067-1077. Open-label cluster-randomised trial in 600 rural Chinese villages. Verbatim: "A total of 20,995 persons were enrolled in the trial"; mean age 65.4, 72.6% with prior stroke, mean follow-up 4.74 years. Stroke rate ratio 0.86 (95% CI 0.77-0.96, P=0.006); major cardiovascular events also lower. 10.1056/NEJMoa2105675
- Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., Karanja, N., & Lin, P.-H. (DASH-Sodium Collaborative Research Group). (2001). Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. New England Journal of Medicine, 344(1), 3-10. Randomized feeding trial (n=412): within both a control diet and the DASH diet, reducing sodium from high to low further lowered blood pressure; the effects of sodium reduction and of the DASH diet were additive, with the largest reduction from combining a low-sodium DASH diet. 10.1056/NEJM200101043440101